• Pfizer entered a global licensing and collaboration agreement with Innovent Biologics to develop 12 early-stage oncology programs, including ADCs and multispecific antibodies.
• Innovent will run development through Phase 1; Pfizer will lead subsequent global development.
• Structure includes four programs licensed globally to Pfizer, four licensed ex-Greater China, and four co-developed with U.S. and Europe profit-sharing.
• Innovent will receive USD 650 million upfront, up to USD 9.85 billion in milestones, royalties up to double digits, and profit share on co-commercialized assets.
• Closing targeted for Q3, subject to regulatory approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605281900BIZWIRE_USPR_____20260527_BW822150) on May 28, 2026, and is solely responsible for the information contained therein.